[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-cancer-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-cancer-patients":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,71,101,134,161,186,215,240],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100645327","effects-of-combined-training-in-prostate-cancer-patients-100645327",false,"NCT07680920","Effects of Combined Training in Prostate Cancer Patients","Effect of Combined Training on Quality of Life, Functional Capacity, Cardiovascular Function, and Body Composition in Prostate Cancer Patients Undergoing Androgen Suppression Therapy: a Randomized Controlled Clinical Trial","Proactive","Inclusion Criteria:\n\nClinical diagnosis of prostate cancer stages I-III; Currently undergoing androgen deprivation therapy (ADT); Aged 40 to 75 years; No participation in research involving physical exercise or any systematic physical exercise intervention during the four months preceding the intervention; Residence in the Greater Florianópolis region, Santa Catarina, Brazil; Provision of written informed consent.\n\nExclusion Criteria:\n\nCurrent participation in a structured physical exercise program; Presence of musculoskeletal disorders or other diseases that may prevent participation in the intervention or the assessment procedures.","MALE","40 Years","75 Years",{"count":21,"type":22},46,"ESTIMATED","INTERVENTIONAL",[25],"NA","Prostate cancer is the most prevalent type among men in Brazil, after non-melanoma skin cancer. One of the main treatment approaches is androgen suppression therapy (AST), which, although effective in controlling tumor growth, leads to several adverse effects such as erectile dysfunction, fatigue, reduced muscle mass, increased body fat percentage, decreased functional capacity and muscle strength, as well as a higher risk of cardiovascular events due to the sharp decline in testosterone and dihydrotestosterone. These factors significantly impair patients' quality of life. Physical exercise has been shown to mitigate such effects; however, in Brazil, only one study has so far evaluated the impact of exercise in men undergoing AST.\n\nGiven this context, the aim of the present study is to assess the effect of supervised physical exercise on quality of life, functional capacity, cardiovascular parameters, handgrip strength, and physical activity levels in men with prostate cancer undergoing AST. A randomized controlled clinical trial will be conducted, with patients allocated into an intervention group (IG) and a control group (CG). Data collection and the exercise intervention will take place at the Rehabilitation Center of the Sports Center at the Federal University of Santa Catarina (UFSC). The IG will participate in a supervised multicomponent exercise program including muscle strength, aerobic capacity, motor coordination, and flexibility, over 12 weeks, with 60-minute sessions three times per week.\n\nOutcomes will be assessed before and after the intervention, covering quality of life (SF-36, EORTC QLQ-BR30, and EORTC QLQ-PR25 questionnaires), functional capacity (submaximal treadmill test, six-minute walk test, timed-up and go, 30-second sit-to-stand, and modified sit-and-reach), cardiovascular parameters (office and ambulatory systolic and diastolic blood pressure, resting heart rate, heart rate variability, flow-mediated dilation, arterial stiffness, and carotid intima-media thickness), body composition, and physical activity level. Adverse events will be recorded weekly. For statistical analysis, sample characterization variables will be examined using Student's t-test, Chi-square, and Fisher's exact test, while intervention outcomes will be analyzed using the generalized estimating equations (GEE) model, with significance set at p\\\u003C0.05, both by intention-to-treat and per-protocol approaches.",[28,29],"Prostate Cancer Patients","Androgen Deprivation Therapy",[31,32,33,34],"prostate cancer","androgen suppression therapy","Physical exercise","combined exercise","NOT_YET_RECRUITING","2026-06-25",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":22},"2026-06-15",{"date":43,"type":22},"2027-06",{"name":45,"class":46},"Universidade Federal de Santa Catarina","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100645130","phase-4-177lu-psma-617-combined-with-darolutamide-in-neoadjuvant-treatment-of-high-risk-localized-prostate-cancer-a-prospective-single-arm-multi-center-clinical-trial-100645130","NCT07677566","177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial","IUNU-PC-123","Inclusion Criteria:\n\n1. Patients must be ≥ 18 and ≤75 years of age\n2. All patients must have a histologically or cytologically diagnosis of prostate cancer，without distant metastasis, and suitable for radical prostatectomy\n3. All patients meet at least one of the following criteria： multi-parameter MRI or PSMA PET \u002F CT shows clinical staging of primary tumor ≥ T2c； Gleason score of primary tumor ≥ 8； prostate specific antigen (PSA) ≥20 ng\u002Fml； Radiographic assessment of regional lymph node metastases (N1)\n4. Eastern Cooperative Oncology Group (ECOG) physical condition score 0- 1\n5. Primary lesion SUVmax ≥ 20.0 as assessed by PSMA-PET examination.\n6. Adequate organ function: Complete Blood Count: White blood cell count (WBC) ≥ 3.0 × 10\\^9\u002FL, platelet count ≥ 100 × 10\\^9\u002FL, hemoglobin ≥ 9 g\u002FdL. Renal Function: Serum creatinine ≤ 2 × ULN. Liver Function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, total bilirubin (TBIL) ≤ 1.5 × ULN. Coagulation Function: International normalized ratio (INR) \\\u003C 1.5.\n7. Voluntary Participation: Participants must voluntarily agree to participate and sign the informed consent form (ICF), indicating their understanding of the purpose of the study and the required procedures, as well as their willingness to participate in the research. Participants must be willing to comply with the prohibitions and restrictions outlined in the study protocol.\n8. Patients of childbearing potential must be willing to take high-efficiency contraceptive measures during the study period and within 120 days after the last dose of treatment\n\nExclusion Criteria:\n\n1. Patients with prostate having neuroendocrine, small cell, or sarcoma-like features are not eligible\n2. Patients with low-risk and medium-risk, localized prostate cancer (the following conditions are met at the same time) are not eligible: prostate specific antigen (PSA) \\\u003C20 ng\u002FmL multiparameter MRI or PSMA PET \u002F CT shows clinical staging of primary tumor \\\u003C T3, Gleason score of primary tumor \\\u003C 8\n3. Patients with clinical or radiological evidence of regional or extra-regional lymph node metastases or bone metastases or visceral metastases (any M1）\n4. Primary lesion SUVmax \\\u003C 20.0 as assessed by PSMA-PET examination.\n5. Patients who have previously received androgen deprivation therapy (medical or surgical) more than 3 months or focal treatment of prostate cancer or prostate cancer radiotherapy or prostate cancer chemotherapy\n6. Patients with severe or uncontrolled concurrent infections\n7. Patients must not have New York Heart Association Class III or IV congestive heart failure at the time of screening. Patients must not have any thromboembolic event, unstable angina pectoris, myocardial infarction within 6 months prior to registration\n8. Uncontrolled severe hypertension, persistently uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection\n9. Patients with a history of other malignancies within the past 5 years, except for prostate cancer, are not eligible; however, cured basal cell carcinoma or squamous cell carcinoma of the skin may be eligible\n10. Patients with mental illness, mental disability, or inability to provide informed consent","18 Years",{"count":56,"type":22},20,[58],"PHASE4","The goal of this clinical trial is to explore the efficacy and safety of darolutamide combined with 177Lu-PSMA-617 in treating high-risk localized prostate cancer patients who are scheduled to undergo radical prostatectomy. The main questions it aims to answer are:\n\nDoes this combination treatment improve the pathological complete response rate (pCR)? What is the minimal residual disease (MRD) rate in these patients? What are the safety profiles and any adverse effects associated with this treatment? Researchers will compare the combination of darolutamide and 177Lu-PSMA-617 to a placebo to see if the combination is effective in treating high-risk localized prostate cancer.\n\nParticipants will:\n\nReceive either darolutamide combined with 177Lu-PSMA-617 or a placebo every day for 12 weeks.\n\nVisit the clinic every 6 weeks for checkups and tests. Keep a diary of their symptoms and any side effects experienced during the treatment.\n\nUndergo imaging tests, including prostate MRI and PSMA PET\u002FCT, before surgery and during follow-up.",[61,28],"Prostate Cancer","2026-06-24",{"date":64,"type":39},"2026-07-01",{"date":64,"type":22},{"date":67,"type":22},"2028-12-31",{"name":69,"class":46},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":79,"minAge":54,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":70},"100612469","cancer-survivors-program-100612469","NCT07253987","Cancer Survivors Program","Cancer Survivors Program: Effectiveness of Monitoring Adverse Events After Completion of Curative Treatment for Breast and Prostate Cancer","SURV-QoL","Inclusion Criteria:\n\n* The patient understands the information provided and agrees to participate in the study.\n* Age 18 years or older.\n* Histologically confirmed invasive breast cancer or invasive prostate cancer.\n* Completion of the acute phase of curative oncological therapy:\n\n  * for breast cancer: curative surgery performed + completed neoadjuvant\u002Fadjuvant chemotherapy and completed adjuvant radiotherapy, if indicated\n  * for prostate cancer: completed radiotherapy with curative intent or radical prostatectomy performed (open, laparoscopic, robotic) or completed adjuvant radiotherapy after prostatectomy\n* The patient is available for follow-up within 12 months of enrollment in the study.\n\nExclusion Criteria:\n\n* Active ongoing oncological therapy (except for (i) adjuvant hormone therapy, (ii) adjuvant targeted therapy (anti-HER2 therapy, CDK4\u002F6i, PARPi, T-DM1), (iii) adjuvant immunotherapy)\n* Neoadjuvant\u002Fadjuvant therapy did not include chemotherapy (breast cancer).\n* Recurrence of cancer\n* Metastatic disease\n* History of other primary malignancy (except for non-melanoma skin cancer)","ALL",{"count":81,"type":22},200,[25],"The questionnaire for assessment of adverse events after completion of cancer treatment, which is being piloted at the Masaryk Memorial Cancer Institute, aims to detect a wide range of adverse effects early on, thus facilitating adequate intervention and planning of follow-up care for all cancer survivors.",[28,85],"Breast Cancer Patients",[87,88,31,89,90],"cancer survivors","breast cancer","neo-\u002Fadjuvant chemotherapy","quality of life","RECRUITING","2026-06-10",{"date":94,"type":39},"2026-06-11",{"date":96,"type":39},"2025-05-05",{"date":98,"type":22},"2026-12-31",{"name":100,"class":46},"Masaryk Memorial Cancer Institute",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100637829","expanding-genetic-access-for-prostate-cancer-survivors-100637829","NCT07618520","Expanding Genetic Access for Prostate Cancer Survivors","Expanding Genetic Access and Guided Education for Prostate Cancer Survivors","ENGAGE","Inclusion Criteria:\n\n* 18-80 years of age\n* At least 6-months post diagnosis with prostate cancer\n* Have not had genetic testing for hereditary cancer\n* Have received care at one of the participating sites in the prior five years\n* Meet National Comprehensive Cancer Network criteria for germline GT\n* Able to read and speak in English\n* Capable of providing informed consent\n* Have internet access (via smartphone, tablet or computer)\n* Comfortable using a computer or mobile phone independently to access information\n\nExclusion Criteria:\n\n* Do not speak English\n* Unable to access the Internet\n* Have previously undergone germline genetic testing for hereditary cancer risk or previously had genetic counseling (GC) and declined genetic testing (GT)\n* Are unable to provide informed consent","80 Years",{"count":111,"type":22},500,[25],"The goal of this study is to increase genetic education and genetic testing for hereditary cancer risk among prostate cancer survivors. The study will:\n\nTest the effectiveness of a digital guide (DG+) vs. print guide (Print+) vs. enhanced usual care (EUC) on engagement in genetic education and uptake of genetic testing.\n\nEvaluate the impact of the DG+ vs. Print+ vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes).\n\nExplore the ways (methods) that influence how participants experience the intervention.\n\nThe main questions this study aims to answer are: which group - the digital guide (DG+) group, print (Print+) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education.\n\nParticipants will be randomly assigned to either the digital guide (DG+) group, the print guide (Print+) group or EUC group. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the three groups to determine which is most most likely to complete genetic testing (GT) and which group engages more with genetic education.",[28,115,116],"Hereditary Cancer","Genetic Testing",[118,119,120,121,122,123],"Prostate cancer","survivorship","genetic counseling","genetic testing","hereditary cancer","Chatbot","2026-05-25",{"date":126,"type":39},"2026-06-01",{"date":128,"type":22},"2026-08-01",{"date":130,"type":22},"2030-07-31",{"name":132,"class":46},"Georgetown University",2,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":140,"minAge":54,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":70},"100632314","phase-2-a-dose-optimization-study-of-enzalutamide-in-elderly-patients-with-advanced-prostate-cancer-100632314","NCT07512076","A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer","Inclusion Criteria:\n\nMain Cohort:\n\n1. Male aged 75 years or older.\n2. Signed Informed Consent Form\n3. Advanced prostate cancer with a Health Canada approved indication for enzalutamide amongst the following:\n\n   1. High-risk biochemical recurrent hormone sensitive prostate cancer (high risk definition: PSA doubling time of ≤9 months and a PSA level of ≥2 ng per milliliter above nadir after radiation therapy or ≥1 ng per milliliter after radical prostatectomy with or without postoperative radiation therapy).\n   2. Metastatic castration-sensitive prostate cancer.\n   3. Non-metastatic castration-resistant prostate cancer (M0CRPC) with a PSA doubling time of ≤9 months\n4. Participants must receive concomitant androgen deprivation therapy with either a Luteinizing hormone-releasing hormone (LHRH) antagonist or agonist, or have had bilateral orchiectomy.\n5. Participant is capable, in the opinion of the investigator, of completing all study assessments and procedures, including blood draws for PK sampling according to the required schedule as per the study protocol as well as PROs.\n\n   1. Note, for patients who speak a language other than English, PROs may be completed with the help of an interpreter, or translated PROs may be substituted, if available in the patient's primary language.\n\nControl Cohort:\n\n1. Age \\\u003C 70 years\n2. Receiving enzalutamide for advanced prostate, for any indication as per Product Monograph\n3. Receiving the same dose of enzalutamide taken daily and fully compliant for ≥ 29 days\n4. Signed Informed Consent Form\n\nExclusion Criteria:\n\nMain Cohort:\n\n1. Metastatic castration-resistant prostate cancer\n2. Pain related to bone metastasis requiring the use of opioid analgesics\n3. Impending spinal cord compression related to metastasis to vertebral column\n4. Painful femoral neck or any other metastasis judged to be at risk of short-term pathological fracture in the investigator's opinion\n5. Co-administration of medications which are moderate to strong CYP2C8 inducers or inhibitors\n6. Co-administration of medications which are moderate to strong CYP3A4 inducers or inhibitors\n7. History of seizure disorder\n8. History of moderate-severe dementia\n9. Performance status \\> ECOG 2\n10. Uncontrolled hypertension (defined as sustained systolic blood pressure above 160 and\u002For diastolic above 100 despite the adequate use of antihypertensive medication)\n11. Participants with a known history of dementia, seizure disorder, intracranial lesions, moderate to severe hepatic impairment, stage ≥ 3 chronic renal failure or stroke will also be excluded\n\nControl Cohort:\n\n1. Unable to provide written informed consent\n2. Receiving a medication which is a moderate-strong CYP2C8 or CYP3A4 inducer or inhibitor","FEMALE",{"count":142,"type":22},26,[144],"PHASE2","This is a phase II, single-centre, pragmatic, non-randomized, dose escalation study to evaluate optimal dose levels of enzalutamide in elderly patients using pharmacokinetic blood sampling concentrations.",[28,147,148],"Elderly Patients","Pharmacokinetic Study",[31,150,151],"enzalutamide","elderly patients","2026-03-31",{"date":154,"type":39},"2026-04-06",{"date":156,"type":22},"2026-04",{"date":158,"type":22},"2027-12",{"name":160,"class":46},"Sunnybrook Health Sciences Centre",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":70},"100599873","phase-1-trial-of-ptvg-hpnivotargeted-ablation-of-resistant-lesions-in-non-castrate-recurrentompc-100599873","NCT07090148","Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC","Pilot Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and PD-1 Blockade, With Targeted Ablation of Resistant Lesions, in Patients With Non-Castrate Recurrent Oligometastatic Prostate Cancer","Inclusion Criteria:\n\n* Participants must be at least 18 years of age with a histologic diagnosis of adenocarcinoma of the prostate\n* Participants must have undergone radical prostatectomy\n* Participants must have completed local therapy by surgery, and any adjuvant\u002Fsalvage radiation therapy (if required), at least 3 months prior to entry, with removal or ablation of all visible disease, including seminal vesical and\u002For local lymph node involvement.\n* Participants must have biochemically recurrent disease defined by the following:\n\n  * PSA doubling time, calculated from most recent 4 serum PSA values (collected up to one year prior to enrollment, at least 2 weeks apart, and all from the same clinical laboratory), must be a positive number (i.e. evidence of PSA rise over time).\n* Participants must have oligometastatic disease, defined as:\n\n  * \\\u003C 3 lesions consistent with metastases as detected by CT of the abdomen\u002Fpelvis and bone scintigraphy (bone scan)\n  * Lesions consistent with metastatic prostate cancer as detected by PSMA PET\u002FCT\n* Participants with a prior history of a second malignancy are eligible provided they have been treated with curative intent and have been free of disease greater than three years. There will be no exclusion for patients with a history of basal cell carcinoma, squamous cell skin cancer, superficial bladder cancer, or other in situ carcinoma that has been adequately treated.\n* Participants who are sexually active must use a reliable form of contraception while on study and for 4 weeks after the last immunization.\n* ECOG performance score \\\u003C 2 and life expectancy of at least 12 months.\n* Participants must have normal hematologic, renal and liver function\n* Participants must be informed of the experimental nature of the study and its potential risks and must sign an IRB-approved written informed consent form indicating such an understanding.\n* Willingness to provide blood samples for immune studies, per study calendar, up to one year after study, even if off treatment.\n\nExclusion Criteria:\n\n* Small cell or other variant prostate cancer histology\n* Participants cannot have evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy or chronic treatment dose corticosteroids (greater than the equivalent of 10 mg prednisone per day), within 3 months of the first vaccination.\n* Seropositive for HIV, hepatitis B (HBV) or hepatitis C (HCV) per patient history due to the immunosuppressive features of these diseases.\n* Prior treatment with an LHRH agonist or nonsteroidal antiandrogen, except in the following circumstances: Neoadjuvant\u002Fadjuvant androgen deprivation therapy administered with radiation therapy or at the time of prostatectomy is acceptable, provided that there was no evidence of PSA progression while on treatment. In this situation, patients must not have received more than 24 months of androgen deprivation treatment. Other treatment with androgen deprivation therapy is prohibited.\n* Serum testosterone at screening \\\u003C 50 ng\u002FdL.\n* Participants must not be concurrently taking other medications or supplements with known hormonal effects, including PC-SPES, megestrol acetate, finasteride, ketoconazole, estradiol, or Saw Palmetto. All other medications with possible anti-cancer effects must be discussed with the PI prior to study entry.\n* Participants previously treated with other potential or experimental therapies for prostate cancer must have discontinued these treatments and completed at least a 4 week washout prior to beginning treatment.\n* Participants must not have known psychological or sociological conditions, addictive disorders or family problems, which would preclude compliance with the protocol.\n* Participants with unstable or severe intercurrent medical conditions or laboratory abnormalities that would impart, in the judgment of the PI, excess risk associated with study participation or study agent administration.\n* Participants who have concurrent enrollment on other phase I, II, or III investigational therapeutic treatment studies for prostate cancer cannot be actively receiving treatment and the last dose cannot be within 4 weeks of day 1. They must be in the follow up phase of the study.",{"count":169,"type":22},14,[171],"PHASE1","The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP (\"vaccine\" or \"DNA vaccine\"), combined with a drug called nivolumab can increase the cancer-fighting ability of a person's immune cells.\n\nThe main question it aims to answer is whether the combination of medicines can get rid of metastatic tumors in participants with non-castrate, recurrent, oligometastatic prostate cancer.\n\nParticipants will undergo:\n\n* Treatment with pTVG-HP\n* Treatment with Nivolumab\n* Radiation Therapy",[28,174,175,176],"Non-castrate Prostate Cancer","Recurrent Prostate Cancer","Oligometastatic Prostate Cancer (OMPC)","2026-03-09",{"date":179,"type":39},"2026-03-11",{"date":181,"type":39},"2026-03-03",{"date":183,"type":22},"2030-10",{"name":185,"class":46},"University of Wisconsin, Madison",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":213,"locationsCount":133},"100305600","phase-2-a-randomised-trial-of-cabazitaxel-docetaxel-mitoxantrone-or-satraplatin-cdms-plus-surgery-for-prostate-cancer-patients-100305600","NCT03258320","A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients","A Phase II-III Study of Neoadjuvant Chemotherapy Involving Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Followed by Surgery for Patients With High Risk Prostate Cancer","Inclusion Criteria:\n\n* 40 ≤ age ≤ 75 years with histologically proven PCa\n* no severe major organ dysfunction\n* WHO performance status of 0 or 1\n* no prior cancer chemotherapy\n* A Clinical Stage ≥ T2c (T2c, N0, M0) of prostate cancer but ideally without diagnosed distant metastasis (according to the 2016 American Joint Committee on Cancer (AJCC) definition of TNM staging system, Staging Manual, Eighth Edition) as determined by a preoperative evaluation that included a pleural computed tomography (CT) scan.\n\nExclusion Criteria:\n\n* age ≥ 76\n* severe major organ dysfunction\n* WHO performance status of \\>1\n* prior cancer chemotherapy\n* Stage IV.",{"count":194,"type":22},300,[144,196],"PHASE3","Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer (CRPC), which is finally refractory to most modalities of clinical intervention with a clinically lethal nature.",[28],[200,201,202,203,204,61,205,206],"Cabazitaxel","Docetaxel","Mitoxantrone","Satraplatin","Surgery","Localized","High Risk","2026-01-08",{"date":209,"type":39},"2026-01-12",{"date":211,"type":39},"2015-01",{"date":158,"type":22},{"name":214,"class":46},"Shanghai Jiao Tong University School of Medicine",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":225,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":70},"100605006","evaluation-of-needs-of-patients-and-care-givers-during-and-after-radiotherapy-of-patients-with-prostate-cancer-100605006","NCT07156903","Evaluation of Needs of Patients and Care-givers During and After Radiotherapy of Patients With Prostate Cancer","Qualitative Erhebung Zur Erfassung Der Bedürfnisse Von Patienten Und Deren Angehörigen während Und Nach Einer Strahlentherapie Bei Prostatakarzinomerkrankung Und Deren Einstellung Und Wünsche bezüglich Einer Prähabilitationsmaßnahme","PrähabPro","Inclusion Criteria:\n\n* Diagnosed Prostate Cancer with curativ intended Radiotherapy\n* min. 18 years\n* sufficient knowledge of German language for participation in interviews\n* Capacity to consent\n\nExclusion Criteria:\n\n* age \\\u003C18 years",{"count":224,"type":22},60,[25],"Exploratory qualitative survey to assess the needs of patients and their relatives during and after radiotherapy for prostate cancer and their attitudes and wishes regarding prehabilitation measures",[28],[229,230],"Qualitative Research","Prehabilitation","2025-09-04",{"date":233,"type":39},"2025-09-05",{"date":235,"type":39},"2025-08-01",{"date":237,"type":22},"2026-11-30",{"name":239,"class":46},"Charite University, Berlin, Germany",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":70},"100605101","a-digitally-distributed-yoga-intervention-in-prostate-cancer-rehabilitation--protocol-for-a-randomized-controlled-trial-100605101","NCT07158138","A Digitally Distributed Yoga Intervention in Prostate Cancer Rehabilitation : Protocol for a Randomized Controlled Trial","A Digitally Distributed Yoga Intervention in Prostate Cancer Rehabilitation (DigiYoga-P): Protocol for a Randomized Controlled Trial","Digiyoga-P","Inclusion Criteria: are men diagnosed with prostate cancer without signs of metastatic disease, treated with curative intent. They should be Swedish-speaking and literate. Participants can be included within two months of diagnosis\n\n\\-\n\nExclusion Criteria:\n\n* are individuals under active surveillance or with advanced disease.",{"count":249,"type":22},220,[25],"Prostate cancer and its treatment can affect psychological, physical, and social quality of life. The most common side effects of the disease and treatment are bowel and urinary problems, sexual issues, and reduced quality of life. These issues can be alleviated with proper treatment and rehabilitation. Stress has been shown to be a significant factor in reduced quality of life.\n\nThe overall aim of the research project is to evaluate and compare the effect of an internet-based yoga intervention for individuals diagnosed with prostate cancer with a control group receiving standard care regarding stress, urinary incontinence, blood pressure, and quality of life. Additional objectives include describing cost-effectiveness and the experience of participating in an internet-based yoga intervention at home.\n\nScientific Questions Does internet-based yoga have any effect on stress, urinary incontinence, blood pressure, and quality of life compared to standard care? Is internet-based yoga a cost-effective intervention from the perspective of healthcare and society compared to standard care? How feasible is internet-based yoga, and how do participants perceive it? Does blood pressure change due to digital yoga, and does the effect persist after one year? Do participants in the intervention group continue practicing yoga after the intervention ends?",[28],[254,255,256,257,31],"RCT","rehabilitation","yoga","Digital","2025-08-28",{"date":233,"type":39},{"date":261,"type":22},"2026-01-10",{"date":263,"type":22},"2030-01-10",{"name":265,"class":46},"Region Örebro County"]